Xofigo
PHONETIC PRONUNCIATION: Xofigo
Description
Xofigo (radium-223 dichloride) is a medication used to treat bone cancer that has spread to the bones from other parts of the body. This medication is typically used as a last resort when other treatments have failed. Xofigo works by targeting the cancerous cells in the bones and delivering radiation to those cells, which can help to slow the growth of the cancer and relieve symptoms. Uses Xofigo is used to treat bone cancer that has spread to the bones from other parts of the body. This type of cancer, known as metastatic castration-resistant prostate cancer (mCRPC), can lead to significant pain and mobility issues, as well as other serious complications. Xofigo is typically used in patients who have already received other treatments, such as chemotherapy or hormonal therapy, and whose cancer has continued to progress despite those treatments. Dosage Xofigo is typically administered as an injection by a healthcare provider. The recommended dose is 55 kBq/kg of body weight, administered once every four weeks for a total of six injections. The exact dosage and frequency of administration may vary depending on the patient's individual needs and response to treatment. Demographic Xofigo is typically used in older adults with metastatic castration-resistant prostate cancer. This type of cancer is more common in older men, with the average age of diagnosis being around 66 years old. Xofigo may also be used in younger patients who have advanced cancer that has not responded to other treatments. Side Effects Like all medications, Xofigo may cause side effects in some patients. Some of the most common side effects of Xofigo include: - Nausea - Diarrhea - Vomiting - Swelling or pain at the injection site - Low blood cell count Less commonly, Xofigo may cause more serious side effects, including: - Bone marrow suppression - Fractures and other bone damage - Increased risk of infection - Kidney problems Interactions Xofigo may interact with other medications or supplements, so it is important to inform your healthcare provider of all medications you are taking before starting Xofigo. Some medications that may interact with Xofigo include: - Chemotherapy drugs - Radiation therapy - Calcium supplements - Vitamin D supplements Generic Options There are currently no generic versions of Xofigo available, as it is a brand-name medication. However, there may be other treatments available for bone cancer that have spread to the bones, depending on the specific type and stage of cancer. Your healthcare provider can provide more information about treatment options and help you determine the best course of action for your individual situation.
Faq for Xofigo
Xofigo (radium Ra 223 dichloride) is a prescription medication used to treat men with prostate cancer that has spread to the bones and is causing symptoms.
Xofigo works by targeting and binding to the areas of bone with cancer cells, delivering radiation to destroy these cells and relieve symptoms associated with bone metastases.
Xofigo is typically given as an injection every four weeks for a total of six injections.
The common side effects of Xofigo include nausea, diarrhea, vomiting, constipation, swelling in the legs, feet, or ankles, low red blood cell counts (anemia), low white blood cell counts (leukopenia), and low platelet counts (thrombocytopenia).
The treatment duration with Xofigo is usually six months, as it involves a total of six injections given once every four weeks.
Coverage for Xofigo may vary depending on insurance plans. It is advisable to check with your insurance provider regarding the coverage and any prior authorization requirements.
Xofigo is not recommended to be used together with chemotherapy. However, it can be prescribed alongside other medications like hormone therapy or radiation.
Xofigo should not be used in people who have a known allergy to radium Ra 223 dichloride or similar drugs. It is essential to inform your healthcare provider about any existing medical conditions or ongoing treatments before starting Xofigo.
Xofigo can be used in elderly patients as long as their overall health allows for it. However, a healthcare professional should assess the potential risks and benefits based on individual circumstances.
Xofigo is only approved for use in men with prostate cancer and is not indicated for women or pediatric patients.